| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01537666 | Inhaled Vancomycin Tolerability, Safety and Pharmacokinetics | PHASE1 | COMPLETED | 25 | — | — | Nov 1, 2011 | Mar 1, 2012 | Mar 31, 2014 | 2 | Australia |
Each participant was monitored regularly for Adverse Events (AEs) throughout the study. The Investigator or designee enquired about AEs by asking participants non-leading questions such as: "How do you feel?" or "Have you had any (other) medical problems since your last visit/assessment?" Additionally, several safety procedures (physical examinations, vital signs, safety laboratory tests, 12-lead ECGs, and spirometry) were conducted on participants at regular intervals. All AEs reported spontaneously by participants or in response to questioning or observation by the Investigator, including those related to safety procedures, were recorded. For each AE, the Investigator recorded the following assessments: seriousness, severity (Mild, Moderate, or Severe), and relationship to study drug (Not Related, Remote, Possible, Probable, or Highly Probable). AEs were considered drug-related if given a relationship of Possible, Probable, or Highly Probable.
| Arm | Type | Description |
|---|---|---|
| Aerovanc 16 mg in healthy volunteers | EXPERIMENTAL | - |
| AeroVanc 32 mg in healthy volunteers | EXPERIMENTAL | - |
| AeroVanc 80 mg in healthy volunteers | EXPERIMENTAL | - |
| IV vancomycin in healthy volunteers | ACTIVE_COMPARATOR | - |
| AeroVanc 32 mg in CF patients | EXPERIMENTAL | - |
| AeroVanc 80 mg in CF patients | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| AeroVanc | DRUG | Vancomycin hydrochloride dry powder for inhalation |
| IV vancomycin hydrochloride | DRUG | Vancomycin hydrochloride solution for intravenous administration |
Inclusion Criteria Healthy Volunteers: 1. Healthy male volunteers between 18 and 50 years of age inclusive. 2. Able to communicate with site personnel and to understand and voluntarily sign the Informed Consent Form. 3. Able and willing to comply with the Protocol, including availability for all sc...